Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn’s disease in China

doi:10.3748/wjg.v32.i8.115291

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 8

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (47)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

HTML

Figures (1-5)

Tables (1-4)

Sum=27

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=4

Feb 28, 2026 (publication date) through Feb 14, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Feb 28, 2026; 32(8): 115291
Published online Feb 28, 2026. doi: 10.3748/wjg.v32.i8.115291

Open in New Tab Full Size Figure Download Figure

Figure 1 Treatment sequence and model structure for moderate to severe Crohn’s disease. ADA: Adalimumab; IFX: Infliximab; UST: Ustekinumab; VDZ: Vedolizumab.

Open in New Tab Full Size Figure Download Figure

Figure 2 Cost-effectiveness scatter plot of different treatment sequences for biologic-naïve Crohn’s disease patients. ADA: Adalimumab; IFX: Infliximab; QALYs: Quality-adjusted life years; UST: Ustekinumab; VDZ: Vedolizumab.

Open in New Tab Full Size Figure Download Figure

Figure 3 Tornado diagram for one-way sensitivity analysis: Sequence 1 (vedolizumab-ustekinumab) vs sequence 3 (adalimumab-ustekinumab) in biologic-naïve Crohn’s disease patients. ADA: Adalimumab; Bio: Biologics; ICER: Incremental cost-effectiveness ratio; IFX: Infliximab; OR: Odds ratio; PBO: Placebo; QALYs: Quality-adjusted life years; SAEs: Serious adverse events; UST: Ustekinumab; VDZ: Vedolizumab.

Open in New Tab Full Size Figure Download Figure

Figure 4 Cost-effectiveness scatter plot of sequence 1 (vedolizumab-ustekinumab) vs sequence 3 (adalimumab-ustekinumab) in biologic-naïve Crohn’s disease patients. PSA: Probabilistic sensitivity analysis; QALYs: Quality-adjusted life years.

Open in New Tab Full Size Figure Download Figure

Figure 5 Cost-effectiveness acceptability curve of treatment sequences vs sequence 1 for biologic-naïve Crohn’s disease patients. QALYs: Quality-adjusted life years.

Citation: Wu Y, Tao LB, Liu C, Wang FX, Yan Y, Sun S. Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn’s disease in China. World J Gastroenterol 2026; 32(8): 115291
URL: https://www.wjgnet.com/1007-9327/full/v32/i8/115291.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i8.115291